Author(s):
Silpa Dilip, Dr. Perraju Bendapudi, Renjitha Bhaskaran, Roshni P R
Email(s):
roshnipr@aims.amrita.edu
DOI:
10.5958/0974-360X.2020.00268.1 
Address:
Silpa Dilip1, Dr. Perraju Bendapudi2, Renjitha Bhaskaran3, Roshni P R4*
14th Semester M.Pharm, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Viswa Vidhyapeetham, Kochi.
2Consultant, Department of Neonatology, Amrita Institute of Medical Sciences and Research Centre, Kochi.
3Lecturer, Department of Biostatistics, Amrita Institute of Medical Sciences and Research Centre, Kochi.
4Assistant Professor, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi.
*Corresponding Author
Published In:
Volume - 13,
Issue - 3,
Year - 2020
ABSTRACT:
Objectives: This study aimed to assess the prevalence of Amikacin induced ototoxicity in neonates in a tertiary care hospital and to elucidate the possible risk factors. Design: A retroprospective study on two hundred and sixty neonates admitted to the neonatal intensive care unit (NICU), who were treated with Amikacin. Ototoxicity was assessed by measuring the hearing impairment in neonates using Brainstem Evoked Response Audiometry (BERA) at the time of discharge. A repeat BERA was done for those who failed during the initial BERA. Results: The prevalence of Amikacin induced ototoxicity in neonates was found to be 11.2% (29 out of 260). Among these 29, only 16 had a follow up BERA and 8 of them showed persistent hearing impairment at the 3 months BERA. Genetic anomalies had showed a significant association with hearing impairment (P value = 0.001). Among the 16 who were diagnosed with a genetic condition 43.8 % of them had hearing impairment.. The value of CRP (mg/dl) during the 1st course of Amikacin therapy had shown a border line significance (P value =0.067) with hearing impairment. Conclusion: Genetic abnormalities have shown a significant relationship with hearing impairment, hence the use of Amikacin in such neonates should be monitored. We attribute the low prevalence rate of ototoxicity in the NICU population, even in the absence of a therapeutic drug monitoring system for Amikacin to the dosage regimen being used and to the good clinical practices being followed in the NICU.
Cite this article:
Silpa Dilip, Dr. Perraju Bendapudi, Renjitha Bhaskaran, Roshni P R. Assessment of amikacin Induced Ototoxicity in a Neonatal ICU Setup-An experience from tertiary care Teaching Hospital in South India. Research J. Pharm. and Tech 2020; 13(3): 1467-1473. doi: 10.5958/0974-360X.2020.00268.1
Cite(Electronic):
Silpa Dilip, Dr. Perraju Bendapudi, Renjitha Bhaskaran, Roshni P R. Assessment of amikacin Induced Ototoxicity in a Neonatal ICU Setup-An experience from tertiary care Teaching Hospital in South India. Research J. Pharm. and Tech 2020; 13(3): 1467-1473. doi: 10.5958/0974-360X.2020.00268.1 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-3-73
REFERENCES:
1.
Kent A, Turner MA,
Sharland M et al. Aminoglycoside toxicity in neonates: something to worry
about?. Expert Rev. Anti Infect. Ther 2014;12: 319–31.
2.
Khan SN and Joseph S: Appropriate Use of
Antibiotics for the Management of Sepsis in Neonates. International
Journal of Pharmaceutical Science and Research. 2012; 3(7): 1928-1934
3.
Gandraa S, Uriab GA, Murkic S, Singh SK et al.
Point prevalence surveys of antimicrobial use among eight neonatal intensive
care units in India: 2016. Available from : URL : https:// www.elsevier.com/locate/ijid
4.
Gouri ZUH, Sharma
D, Berwal PK et al. Hearing impairment
and its risk factors by newborn screening in north-western India. Matern Health
Neonatol Perinatol 2015; 1:17
5.
Olusanyaa BO, Luxona LM,
Wirzb SL et al. Benefits and challenges
of newborn hearing screening for developing countries. Int. J. Pediatr. Otorhinolaryngol 2004; 68: 287—305.
6.
Ahmed S, Waqas M, Manzoor T, Basheer F.Hearing Assessment with BERA in Infants who had
Received Amikacin. Pakistan Journal of
Otolaryngology 2014;30:47-49
7.
Micromedex Neofax
Essentials 2014
8. Ahmed S, Waqas M, Manzoor T,
Basheer F. Pakistan Journal of
Otolaryngology 2014;30:47-49
9. Engler D, Schellack N, Naude
A, Gous A. A pilot study on the use of Amikacin in neonates:who should be
monitored for ototoxicity ?. Southern African Journal of Infectious Disease 2016;30:72-76.
10. Maqbool M, Najar BA, Gattoo
I, Chowdhary J. Screening for hearing impairment in high risk neonates: a
hospital based study. J Clin Diagn Res 2015;9:18-21
11. Maqbool M, Najar BA, Gattoo
I, Chowdhary J. Screening for hearing impairment in high risk neonates: a
hospital based study. J Clin Diagn Res 2015;9:18-21
12.
Alaee E, Sirati
M, Taziki MH et al. Risk Factors for Sensorineural Hearing Loss Among High-Risk
Infants in Golestan Province, Iran in 2010 – 2011.Iran Red Crescent Med J 2015;
17: e20419
13.
Yoshikawa S, Ikeda K, Kudo T, Kobayashi K. The effects of hypoxia,
premature birth, infection, ototoxic drugs,circulatory system and congenital
disease on neonatal hearing loss. Auris Nasus Larynx .2004;31: 361–368.
14.
Seniuk KW, Greczka G, Dabrowski P, Harris JS,
Mazela J. Hearing impairment in premature newborns -Analysis based on the
national hearing screening database in Poland. PLoS ONE 2017; 12:
15.
Maharani N L P, Haksari E L, Artana W D. Risk
factors for hearing loss in neonates. Paediatr. Indones 2015; 55
16.
Zamani A, Daneshjou K, Ameni A, Takand J.
Estimating the incidence of neonatal hearing loss in high risk neonates.Acta
Med Iran 2004;42:176-180
17.
Sathyabhama J, Karat A. A study on neonatal hearing loss using transient evoked otoacoustic
emissions. J. Evolution Med. Dent.
Sci 2016;5:871-75.